Your browser doesn't support javascript.
loading
Evaluating the effect of antidiabetic treatment on haemostatic and fibrinolytic parameters among type 2 diabetics in Ilorin, Nigeria
Abolarin, A T; Olawumi, H O; Durotoye, I A; Olarinoye, J K; Olufemi-Aworinde, K J.
  • Abolarin, A T; Department of Haematology and Blood Transfusion, Bowen University Teaching Hospital, Ogbomosho, Oyo State, Nigeria1insulin deficiency, resistance or both. It has grown to epidemic proportions in the past few decades with 1-3rapidly rising incidence and prevalence rates.Global projections estimate 109% rise in prevalence in Africa, and about 41 million Africans are predicted to be living with Diabetes by the year 1,42035.Type 2 Diabetes Mellitus is a hypercoagulable state that is accompanied by notable changes to all aspects of the haemostatic mechanism, including. Oyo State. NG
  • Olawumi, H O; Department of Haematology and Blood Transfusion, University of Ilorin Teaching Hospital, Kwara State. Kwara State. NG
  • Durotoye, I A; Department of Haematology and Blood Transfusion, University of Ilorin Teaching Hospital, Kwara State. Kwara State. NG
  • Olarinoye, J K; Department of Internal Medicine, University of Ilorin Teaching Hospital. Kwara State. NG
  • Olufemi-Aworinde, K J; Department of Haematology, Ladoke Akintola University of Technology, Ogbomoso, Oyo State. Oyo State. NG
Ibom Medical Journal15 ; 15(3): 252-258, 2022. tales, figures
Article in English | AIM | ID: biblio-1398765
ABSTRACT

Background:

Type 2 Diabetes Mellitus is a disease of epidemic proportions and many patients are at a great risk of premature mortality and complication of atherothrombotic disorders affecting coronary, cerebral and peripheral arterial trees. Increased Plasminogen Activator Inhibitor Type 1 inhibits fibrinolysis and predicts cardiovascular risk in those living with Type 2 Diabetes. This study aimed to determine the effect of antidiabetic treatment on haemostatic and fibrinolytic parameters among Type 2 Diabetic subjects in Ilorin.

Methods:

This was a comparative cross-sectional study involving 78 Type 2 diabetic patients, (39 treatment naïve, 39 treatment experienced). Full blood count was performed using Sysmex XP300 while Prothrombin time was determined using one stage test of Owren. Activated partial thromboplastin time was determined by method of Proctor and Rapaport. Fibrinogen and Plasminogen Activator Inhibitor type-1 were assayed using AssayMax Human Fibrinogen ELISAand AssayMax Human PAI-1 ELISAkit. Data Analysis was done using SPSS version 25.0.

Results:

Mean PAI-1 levels were significantly higher in treatment naïve diabetics when compared to treatment experienced diabetics (2.44 ±2.57 vs 2.51±1.47 ng/ml p=0.002) as were fibrinogen levels (434.65±366.15 vs 482.24± 299.64mg /dl; p = 0.048). PAI -1 levels were lowest among diabetics treated with Metformin + DPP4 inhibitors, while fibrinogen levels were lowest among those treated with Metformin + sulfonylurea combination.

Conclusion:

Oral hypoglycaemic treatment, combination therapy in particular, improves fibrinolysis in type 2 diabetics thereby reducing the risk of cardiovascular disease in type 2 diabetes mellitus patients
Subject(s)

Full text: Available Index: AIM (Africa) Main subject: Fibrinolysis / Fibrinolytic Agents Type of study: Observational study / Prognostic study / Risk factors Limits: Humans Language: English Journal: Ibom Medical Journal15 Year: 2022 Type: Article Institution/Affiliation country: Department of Haematology and Blood Transfusion, Bowen University Teaching Hospital, Ogbomosho, Oyo State, Nigeria1insulin deficiency, resistance or both. It has grown to epidemic proportions in the past few decades with 1-3rapidly rising incidence and prevalence rates.Global projections estimate 109% rise in prevalence in Africa, and about 41 million Africans are predicted to be living with Diabetes by the year 1,42035.Type 2 Diabetes Mellitus is a hypercoagulable state that is accompanied by notable changes to all aspects of the haemostatic mechanism, including/NG / Department of Haematology and Blood Transfusion, University of Ilorin Teaching Hospital, Kwara State/NG / Department of Haematology, Ladoke Akintola University of Technology, Ogbomoso, Oyo State/NG / Department of Internal Medicine, University of Ilorin Teaching Hospital/NG

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: AIM (Africa) Main subject: Fibrinolysis / Fibrinolytic Agents Type of study: Observational study / Prognostic study / Risk factors Limits: Humans Language: English Journal: Ibom Medical Journal15 Year: 2022 Type: Article Institution/Affiliation country: Department of Haematology and Blood Transfusion, Bowen University Teaching Hospital, Ogbomosho, Oyo State, Nigeria1insulin deficiency, resistance or both. It has grown to epidemic proportions in the past few decades with 1-3rapidly rising incidence and prevalence rates.Global projections estimate 109% rise in prevalence in Africa, and about 41 million Africans are predicted to be living with Diabetes by the year 1,42035.Type 2 Diabetes Mellitus is a hypercoagulable state that is accompanied by notable changes to all aspects of the haemostatic mechanism, including/NG / Department of Haematology and Blood Transfusion, University of Ilorin Teaching Hospital, Kwara State/NG / Department of Haematology, Ladoke Akintola University of Technology, Ogbomoso, Oyo State/NG / Department of Internal Medicine, University of Ilorin Teaching Hospital/NG